Ohio is currently home to 3219 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)
NCT06319287
Recruiting
A Phase 2a Multi-Center, Prospective, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Topically Applied PEP-TISSEEL in Subjects with Diabetic Foot Ulcers (DFU)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Professional Education & Research Institute (PERI), Blue Ash, Ohio
Conditions: Diabetic Foot Ulcer
Register for Updates
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275
Recruiting
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Register for Updates
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
Recruiting
This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide may have antineoplastic activity which may help block the formation o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Register for Updates
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia
NCT05745883
Recruiting
This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Centricity Research, Columbus, Ohio
Conditions: Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
Register for Updates
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
NCT05020912
Recruiting
The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Basal Cell Carcinoma
Register for Updates
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
NCT04747626
Recruiting
A prospective, single-center, non-blind, non-randomized safety and feasibility study of the hybrid repair of thoracic aortic pathologies requiring repair of the aortic arch proximal to the origin of innominate artery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Thoracic Aortic Aneurysm, Aortic Dissection, Congenital Aortic Anomaly
Register for Updates
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
Recruiting
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Gender:
ALL
Ages:
All
Trial Updated:
11/13/2024
Locations: Clinical Trial Site, Columbus, Ohio
Conditions: Atypical Hemolytic-Uremic Syndrome
Register for Updates
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
NCT06426628
Recruiting
The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? * Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is c... Read More
Gender:
ALL
Ages:
Between 29 years and 85 years
Trial Updated:
11/12/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Pulmonary Nodule, Solitary, Lung Cancer
Register for Updates
Development of Web-Based Mind-Body Trainings for Adults With Subjective Concerns
NCT06410807
Recruiting
The goal of this observational study is to develop online, self-paced mindfulness (iMBSR) and lifestyle education (iLifeEd) programs for adults with cognitive concerns. Participants will engage in focus groups to discuss healthy living, web-based behavioral interventions, intervention content/format and ideal outcomes after engaging in behavioral interventions that promote healthy living. Additionally, participants will provide feedback on the protocol and online platform for either iMBSR or iLi... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/12/2024
Locations: Department of Psychology, The Ohio State University, Columbus, Ohio
Conditions: Aging, Focus Groups
Register for Updates
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT06026332
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Ferring Investigational Site, Gahanna, Ohio
Conditions: Bladder Cancer
Register for Updates
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194
Recruiting
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: The Ohio State University James Cancer Hospital & Solove Research Institute, Columbus, Ohio
Conditions: Oral Mucositis
Register for Updates
Incremental Hemodialysis: The TwoPlus Trial
NCT05828823
Recruiting
This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function. The study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Cleveland Clinic, Case Western Reserve University (CWRU), Cleveland, Ohio
Conditions: End-Stage Kidney Disease
Register for Updates